![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1535302
DNA ½ÃÄö½Ì ½ÃÀå ±Ô¸ð, Á¡À¯À², ¿¹Ãø, µ¿Ç⠺м® : Á¦Ç°º°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(-2031³â)DNA Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Kits & Reagents [DNA Extraction, Library Preparation, QC], Instruments, Software), Technology (NGS, Sanger), Application (Clinical, Research) End User - Global Forecast to 2031 |
¼¼°èÀÇ DNA ½ÃÄö½Ì ½ÃÀåÀº 2024-2031³â CAGRÀÌ 11.8%·Î, 2031³â±îÁö 213¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÌ º¸°í¼´Â ±¤¹üÀ§ÇÑ 2Â÷ ¹× 1Â÷ ¿¬±¸¿Í ½ÃÀå ½Ã³ª¸®¿À¿¡ ´ëÇÑ ½ÉÃþ ºÐ¼®À» ÅëÇØ ÁÖ¿ä »ê¾÷ ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, µµÀü °úÁ¦ ¹× ±âȸ ºÐ¼®À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.
DNA ½ÃÄö½Ì ½ÃÀåÀÇ ¼ºÀåÀº ½ÃÄö½Ì ºñ¿ë °¨¼Ò, ¾Ï ¹× À¯Àü¼º ÁúȯÀÇ ¹ßº´·ü Áõ°¡, Áø´Ü ¹× ¸ÂÃã ÀÇ·á¿¡ ´ëÇÑ DNA ½ÃÄö½Ì Ȱ¿ë Áõ°¡, Á¦¾à R&D ÅõÀÚ Áõ°¡, À¯¸®ÇÑ ±ÔÁ¦ ¹× »óȯ Á¤Ã¥, ³ôÀº ÀÇ·áºñ ÁöÃâ, ½ÃÄö½Ì ±â¼úÀÇ ¹ßÀü, ÀÓ»ó ¹× ¿¬±¸ ¿ëµµ¿¡¼ÀÇ ½ÃÄö½Ì ±â¼ú Ȱ¿ëÀ» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎ Áö¿ø ±¸»ó µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ½ÃÄö½Ì ¼Ò¸ðǰ ºñ¿ë, Á¤¹ÐÀǷḦ À§ÇÑ ½Ç¿ëÀûÀÎ µ¹¿¬º¯ÀÌ ½Äº° ÇѰè, DNA ¿°±â¼¿ ±â¹Ý Áø´Ü°ú °ü·ÃµÈ À±¸®Àû, ¹ýÀû ¹®Á¦ µîÀÌ ÀÌ·¯ÇÑ ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ DNA ¿°±â¼¿ ºÐ¼®ÀÇ ¿ëµµ È®´ë, ±¤¹üÀ§ÇÑ À¯Àüü ÇÁ·ÎÁ§Æ®¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø, Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ ÀÎ½Ä ¹× äÅà Áõ°¡, ½ÅÈï ½ÃÀåÀÇ °æÁ¦ ¼ºÀå µîÀº ÀÌ ½ÃÀå¿¡¼ »ç¾÷À» ¿î¿µÇÏ´Â ±â¾÷¿¡°Ô ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ±ÔÁ¦ÀÇ ºÒÈ®½Ç¼º, ¼Ò±Ô¸ð ½ÇÇè½ÇÀÇ Àü¹®¼º°ú ½ÃÄö½Ì ´É·ÂÀÇ ÇѰè, ½ÅÈï ½ÃÀå¿¡¼ÀÇ ½ÃÄö½Ì Àü¹®°¡ ºÎÁ·, NGS ÀÎÇÁ¶ó¿¡ ÇÊ¿äÇÑ ¸·´ëÇÑ ÀÚº» µîÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÌ ½ÃÀåÀÇ ÁÖ¿ä µ¿ÇâÀº ½ÅÈï DNA ½ÃÄö½Ì ±â¾÷ÀÌ ±â¼ú ¹ßÀü°ú ºñ¿ë Àý°¨¿¡ ÁýÁßÇϰí ÀÖÀ¸¸ç, ÁÖ¿ä ±â¾÷ÀÌ ÈÞ´ë¿ë ¹× ½Ç½Ã°£ ½ÃÄö½Ì ±â¼ú °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù.
ÀÌ º¸°í¼´Â ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í Áö¿ªº° ÀÔÁö, ±×¸®°í Áö³ ¼ö³â°£(2021-2024³â) ±â¾÷ÀÌ Ã¤ÅÃÇÑ ÁÖ¿ä ¼ºÀå Àü·«¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Æò°¡¸¦ ¹ÙÅÁÀ¸·Î °æÀï ±¸µµ¸¦ Á¦°øÇÕ´Ï´Ù. ¼¼°èÀÇ DNA ½ÃÄö½Ì ½ÃÀå¿¡¼ »ç¾÷À» ¿î¿µÇϰí ÀÖ´Â ÁÖ¿ä ±â¾÷Àº Illumina, Inc.(¹Ì±¹), Thermo Fisher Scientific Inc.(¹Ì±¹), F. Hoffmann-La Roche Ltd.(½ºÀ§½º), Revvity, Inc.(½ºÀ§½º), Revvity, Inc.(¹Ì±¹), QIAGEN N.V.(³×´ú¶õµå), Agilent Technologies, Inc.(¹Ì±¹), Pacific Biosciences of California, Inc.(¹Ì±¹), Danaher Corporation(¹Ì±¹), Bio-Rad Laboratories, Inc.(¹Ì±¹), Oxford Nanopore Technologies Plc.(¿µ±¹), MGI Tech Co.Ltd.(Áß±¹)ÀÔ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ Á¶»çÇÑ Á¦Ç° Áß ¼Ò¸ðǰ ºÎ¹®Àº 2024³â DNA ½ÃÄö½Ì ½ÃÀåÀ» Àå¾ÇÇÏ¿© Àüü Á¡À¯À²ÀÇ 73.4%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Å« ½ÃÀå Á¡À¯À²Àº ÃÖÁ¾»ç¿ëÀÚÀÇ ¼Ò¸ðǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ½Ã·á Áغñ Àç·áÀÇ ºó¹øÇÑ »ç¿ë, Àú·ÅÇÑ °¡°Ý Áõ°¡, À¯Àüü ¸ÅÇÎ ÇÁ·Î±×·¥ÀÇ È®´ë¿¡ ±âÀÎÇÕ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ Á¶»çÇÑ ¿ëµµ Áß ¿¬±¸ ¹× ±âŸ ¿ëµµ°¡ 2024³â DNA ½ÃÄö½Ì ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, Àüü ½ÃÀåÀÇ 67.2%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº ½ÃÀå Á¡À¯À²ÀÇ ¹è°æ¿¡´Â ¿°±â¼¿ ºÐ¼® ¹æ¹ýÀÇ ºñ¿ë °¨¼Ò, Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ ½Å¾à °³¹ß¿¡ ´ëÇÑ R&D ÅõÀÚ Áõ°¡, ´Ù¾çÇÑ ÀÓ»ó ¹× ¿¬±¸ ȯ°æ¿¡¼ÀÇ NGS Ȱ¿ë È®´ë, ¾à¸®ÇÐÀû Ç¥Àû ½Äº°, Ä¡·á °¡¼³ °ËÁõ, ºÐÀÚ ºÎÀ§¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ¾ïÁ¦ ÈÇÕ¹°ÀÇ ÀáÀçÀû ¾ÈÀü¼º¼º Æò°¡¿¡ ÀÎÆ÷¸Åƽ½º ¼Ö·ç¼ÇÀ» Àû¿ëÇÏ´Â µîÀÇ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ Á¶»çÇÑ ÃÖÁ¾»ç¿ëÀÚ Áß Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ ºÎ¹®Àº 2024³â DNA ¿°±â¼¿ ºÐ¼® ½ÃÀåÀÇ 44.7%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº ½ÃÀå Á¡À¯À²Àº Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ R&D ºñ¿ë Áõ°¡¿Í ¸¸¼ºÁúȯÀÇ È®»êÀ¸·Î ÀÎÇØ Â÷¼¼´ë ½ÃÄö½Ì Á¦Ç° äÅÃÀÌ °¡¼Óȵǰí Àֱ⠶§¹®ÀÔ´Ï´Ù.
¼¼°è DNA ½ÃÄö½Ì ½ÃÀåÀÇ Áö¿ªº° ½Ã³ª¸®¿À¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®Àº 5°³ ÁÖ¿ä Áö¿ª(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«)¿¡ ´ëÇÑ »ó¼¼ÇÑ ÁúÀû ¹× ¾çÀû ÀλçÀÌÆ®¿Í °¢ Áö¿ªÀÇ ÁÖ¿ä ±¹°¡¸¦ ´Ù·ç°í ÀÖÀ¸¸ç, 2024³â ºÏ¹Ì°¡ Àüü Á¡À¯À²ÀÇ 49.0%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù, ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ 2024³â¿¡´Â ¹Ì±¹ÀÌ ºÏ¹Ì DNA ½ÃÄö½Ì ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ³ôÀº ½ÃÀå Á¡À¯À²Àº À¯Àüü ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø, ¿°±â¼¿ ±â¹Ý ¿¬±¸ÀÇ ¿ëµµ È®´ë, Â÷¼¼´ë ¿°±â¼¿ ºÐ¼® ±â¼úÀÇ ¼±µµÀû °ø±Þ¾÷ü Á¸Àç, Á¦¾à ¹× ¹ÙÀÌ¿À Á¦¾à ±â¾÷ÀÇ ¿¬±¸ ÅõÀÚ Áõ°¡, ¿°±â¼¿ ºÐ¼® ºñ¿ë °¨¼Ò, ÷´Ü ¿°±â¼¿ ºÐ¼® Á¦Ç° ¹× ¼Ö·ç¼ÇÀÇ Æø³ÐÀº °¡¿ë¼º, ¾Ï ¹ßº´·ü °¨¼Ò, ¾Ï ¹ßº´·ü Áõ°¡ µî ´Ù¾çÇÑ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ¿ë °¡´É¼º, ¾Ï ¹ßº´·ü Áõ°¡, ÀÌ Áö¿ªÀÇ ¿ìÈ£ÀûÀÎ »óȯ ȯ°æ µî ¿©·¯ ¿äÀÎÀÌ ÀÛ¿ëÇÑ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
DNA ½ÃÄö½Ì ½ÃÀå Æò°¡ - Á¦Ç°º°
ÁÖ: ±âŸ ŰƮ ¹× ½Ã¾à¿¡´Â Èñ¼® ¿ÏÃæ¾×, DNA Ç¥ÁØ, DNA Á¤È ½Ã¾à, Ç¥Àû ³óÃà ½Ã¾à ¹× ±âŸ ½Ã¾àÀÌ Æ÷ÇԵ˴ϴÙ.
DNA ½ÃÄö½Ì ½ÃÀå Æò°¡ - ±â¼úº°
ÁÖ: ±âŸ NGS ±â¼ú ³ª³ëÆ÷¾î ½ÃÄö½Ì ¹× AVITI ½ÃÄö½Ì
Âü°í: ±âŸ NGS ±â¼ú ³ª³ëÆ÷¾î ½ÃÄö½Ì ¹× AVITI ½ÃÄö½ÌDNA ½ÃÄö½Ì ½ÃÀåÀÇ Æò°¡ - ¿ëµµº°
ÁÖ: ±âŸ ¿ëµµ¿¡´Â ½Äǰ ¹Ì»ý¹°ÇÐ, ½Äǰ ¹× À½·á »ê¾÷ÀÇ ¹Ì»ý¹° ºÐ¼®, ȯ°æ Á¶»ç µîÀÌ ÀÖ½À´Ï´Ù.
ÁÖ: ±âŸ ÀÓ»ó ¿ëµµ¿¡´Â ½Å°æ Áúȯ, Èñ±ÍÁúȯ, ´ë»ç ¹× ¸é¿ª ÁúȯÀÇ À¯ÀüÀÚ ÀÌ»ó °ËÃâÀÌ Æ÷ÇԵ˴ϴÙ.
DNA ½ÃÄö½Ì ½ÃÀå Æò°¡ - ÃÖÁ¾»ç¿ëÀÚº°
ÁÖ: ±âŸ ÃÖÁ¾»ç¿ëÀÚ¿¡´Â ¹ýÀÇÇÐ ¿¬±¸¼Ò ¹× º¸¾È ±â°ü, ½Äǰ ¹× À½·á ȸ»ç, ³ó¾÷ ȸ»ç µîÀÌ Æ÷ÇԵ˴ϴÙ.
DNA ½ÃÄö½Ì ½ÃÀå Æò°¡ - Áö¿ªº°
DNA Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Kits & Reagents [DNA Extraction, Library Preparation, QC], Instruments, Software), Technology (NGS, Sanger), Application (Clinical, Research) End User-Global Forecast to 2031
The global DNA sequencing market is projected to reach $21.30 billion by 2031 at a CAGR of 11.8% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.
The DNA sequencing market's growth is driven by several factors, including the decreasing costs of sequencing, the rising incidence of cancer and genetic disorders, the rising use of DNA sequencing in diagnostics and personalized medicine, increased pharmaceutical R&D investments, favorable regulatory and reimbursement policies, high healthcare expenditures, advances in sequencing technology, and supportive government initiatives aimed at promoting the use of sequencing technology in clinical & research applications. However, factors such as the high cost of sequencing consumables, limited identification of actionable mutations for precision medicine, and ethical and legal concerns related to DNA sequencing-based diagnostics restrain this growth.
Moreover, the expanding applications of DNA sequencing, government support for extensive genomic projects, growing awareness and adoption of targeted therapies, and economic growth in emerging markets are anticipated to offer growth opportunities for companies operating in this market. However, regulatory uncertainties, limited expertise & sequencing capabilities among smaller laboratories, a shortage of sequencing professionals in developing regions, and the substantial capital required for NGS infrastructure are some of the challenges impeding the market's growth.
Key trends in this market include the focus of emerging DNA sequencing companies on technological advancements and cost reduction and the emphasis by major players on developing portable and real-time sequencing technologies.
The report offers a competitive landscape based on an extensive assessment of the key players' product portfolios and geographical presence and the key growth strategies adopted by them over the past few years (2021-2024). The key players operating in the global DNA sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).
Among the offerings studied in this report, in 2024, the consumables segment is projected to dominate the DNA sequencing market, capturing 73.4% of the total share. The significant market share is attributed to the growing demand for consumables from end users, frequent use of sample preparation materials, increasing affordability, and the expansion of genome mapping programs.
Among the applications studied in this report, in 2024, the research & other applications segment is projected to dominate the DNA sequencing market, capturing 67.2% of the total share. The significant market share is attributed to several factors: the declining cost of sequencing procedures, increased R&D investments by pharmaceutical and biotechnology companies in drug discovery, the expanding use of NGS in various clinical and research settings, and the application of informatics solutions to identify pharmacological targets, validate therapeutic hypotheses, and assess the potential safety of inhibitory compounds targeting molecular sites.
Among the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is projected to dominate the DNA sequencing market, capturing 44.7% of the total share. The significant market share is attributed to increased R&D expenditures by pharmaceutical & biotechnology companies and the growing prevalence of chronic diseases, which are fueling the adoption of next-generation sequencing products.
An in-depth analysis of the geographical scenario of the global DNA sequencing market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is projected to dominate the market, capturing 49.0% of the total share. Additionally, in 2024, the U.S. is expected to dominate the DNA sequencing market in North America. The region's significant market share can be attributed to several factors, including supportive government initiatives for genomic research, expanding applications of sequencing-based studies, the presence of leading next-generation sequencing technology providers, rising research investments by pharmaceutical and biopharmaceutical companies, decreasing sequencing costs, wide availability of advanced sequencing products and solutions, increasing cancer prevalence, and a favorable reimbursement environment in the region.
DNA Sequencing Market Assessment-by Offering
Note: Other Kits & Reagents Include dilution buffers, DNA standards, reagents for DNA cleanup, target enrichment, and other reagents
DNA Sequencing Market Assessment -by Technology
Note: Other NGS Technologies Nanopore Sequencing and AVITI Sequencing
DNA Sequencing Market Assessment -by Application
Note: Other Applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies.
Note: Other Clinical Applications include the detection of genetic aberrations in neurological disorders, rare diseases, and metabolic and immune disorders.
DNA Sequencing Market Assessment-by End User
Note: Other End Users include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.
DNA Sequencing Market Assessment-by Geography